Amylyx Pharmaceuticals (AMLX) 2025 Conference Transcript

Amylyx Pharmaceuticals (AMLX) 2025 Conference May 13, 2025 04:55 PM ET Speaker0 Reduces, you know, insulin and raises the blood sugar nadir, which is particularly important in diseases of hypoglycemia. It is FDA breakthrough therapy designation in both post bariatric hypoglycemia and congenital hyperinsulinism. And our focus right now is on post bariatric hypoglycemia, where there's been five prior trials, all of which showed significant effects on glucose and insulin. We're now conducting the phase three t ...